<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584125</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002132</org_study_id>
    <nct_id>NCT04584125</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ex Vivo Corneal Cross-Linking of Donor Corneal Tissue Used For a Penetrating Keratoplasty</brief_title>
  <acronym>EVOKE</acronym>
  <official_title>Open-Label Pilot Clinical Trial to Evaluate the Safety and Efficacy of Ex Vivo Corneal Cross-Linking of Donor Corneal Tissue Used for a Penetrating Keratoplasty in Keratoconus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph B. Ciolino, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will assess the safety and efficacy of crosslinking donor corneal tissue&#xD;
      in participants who have undergone corneal transplantation for keratoconus. Crosslinking is a&#xD;
      procedure that stabilizes the biomechanical properties of the cornea; as a result, the cornea&#xD;
      stiffens. It has been shown that this procedure stabilizes the cornea of patients with&#xD;
      keratoconus or corneal ectasias. The FDA currently approves crosslinking for patients with&#xD;
      progressive keratoconus and corneal ectasia following refractive surgery. Keratoconus has&#xD;
      been found to recur in corneas that underwent corneal transplantation. Ex vivo crosslinking&#xD;
      of donor corneal tissue for patients with keratoconus undergoing penetrating keratoplasty&#xD;
      could stabilize the cornea and reduce the risk of recurrence of keratoconus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, ten patients with keratoconus who will undergo their first corneal transplant&#xD;
      surgery in the study eye will be included. When a screened participant meets the inclusion&#xD;
      and exclusion criteria to be enrolled in the study, the investigator will request a cornea&#xD;
      from the central eye bank. The eye bank will then prepare and crosslink the corneal tissue&#xD;
      with riboflavin (Vitamin B2) and ultraviolet A (UVA) light. This prepared corneal tissue will&#xD;
      be used for the corneal transplant of the patients. Subjects will be followed up&#xD;
      post-operatively by the site investigators with a follow-up period of 24 months and standard&#xD;
      of care follow-up every six months for up to 3 years or until study closure. The&#xD;
      investigators will monitor for systemic and ocular adverse events at all follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, single-center, pilot clinical trial to assess the safety and efficacy of ex vivo corneal crosslinking of donor corneal tissue used for penetrating keratoplasty in patients with keratoconus. The study will include 10 participants; these individuals will receive the previously crosslinked corneal tissue for their corneal transplant. Participants will receive close follow-up for up to two years for evaluation of safety and efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by ocular infection, delayed wound healing time, or graft rejection</measure>
    <time_frame>24 months</time_frame>
    <description>Safety assessed by the occurrence of the following adverse events: post-operative microbial keratitis, graft rejection or failure, delayed wound healing greater than 4 weeks, or ulcerative keratitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by refractive measurements</measure>
    <time_frame>24 months</time_frame>
    <description>Effectiveness assessed by refractive and topographic astigmatism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by tomography</measure>
    <time_frame>24 months</time_frame>
    <description>Effectiveness assessed by the stability of tomographic measurements: maximum keratometry, anterior mean keratometry, posterior mean keratometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by visual acuity</measure>
    <time_frame>24 months</time_frame>
    <description>Effectiveness assessed by best spectacle-corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by the need for rigid gas permeable contact lens</measure>
    <time_frame>24 months</time_frame>
    <description>Effectiveness assessed by the percent of participants that require rigs gas permeable contact lens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Ex vivo cross linking of donor corneal tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The donor corneal tissue used in the penetrating keratoplasty procedures will previously undergo ex vivo crosslinking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146%</intervention_name>
    <description>A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 5 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.</description>
    <arm_group_label>Ex vivo cross linking of donor corneal tissue</arm_group_label>
    <other_name>PHOTREXA VISCOUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Willing and able to comply with study assessments for the full duration of the study.&#xD;
&#xD;
          -  Age ≥18 years but ≤50 years&#xD;
&#xD;
          -  History of keratoconus (without a previous transplant) requiring a penetrating&#xD;
             keratoplasty&#xD;
&#xD;
          -  Willing to commit to not having further cross-linking, corneal relaxing incisions,&#xD;
             intacs, or corneal laser vision correction during the course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years &gt;50&#xD;
&#xD;
          -  Inability to provide written informed consent and comply with study assessments for&#xD;
             the full duration of the study&#xD;
&#xD;
          -  Participation in another simultaneous interventional medical investigation or trial&#xD;
&#xD;
        Systemic&#xD;
&#xD;
          -  History of Stevens-Johnson syndrome or ocular pemphigoid&#xD;
&#xD;
          -  Signs of current infection, including fever and current treatment with antibiotics&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactating&#xD;
&#xD;
          -  Pre-menopausal sexually active women not using adequate contraception (Reliable&#xD;
             intrauterine devices, hormonal contraception or a spermicide in combination with a&#xD;
             barrier method)&#xD;
&#xD;
        Recipient Eye&#xD;
&#xD;
          -  Corneal or ocular surface infection within 30 days prior to study entry&#xD;
&#xD;
          -  History of previous cross-linking&#xD;
&#xD;
          -  History of previous corneal transplant&#xD;
&#xD;
          -  Non-healing epithelial defect of at least 0.5x0.5 mm in host corneal bed lasting ≥6&#xD;
             weeks preoperatively&#xD;
&#xD;
          -  Ocular or periocular malignancy&#xD;
&#xD;
          -  Lid abnormalities that in the opinion of the investigator could confound the study&#xD;
             results and these include clinically significant ectropion, lagophthalmos,&#xD;
             cicatrization, entropion, and rosacea&#xD;
&#xD;
          -  Neurotrophic cornea&#xD;
&#xD;
          -  Monocular&#xD;
&#xD;
          -  Uncontrolled glaucoma&#xD;
&#xD;
          -  Glaucoma filtering devices or trabeculectomies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph B Ciolino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph B Ciolino, MD</last_name>
    <phone>(617) 573-3938</phone>
    <email>Joseph_Ciolino@MEEI.HARVARD.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Fitzgerald</last_name>
    <phone>617-573-6971</phone>
    <email>Ellen_Fitzgerald@MEEI.HARVARD.EDU</email>
  </overall_contact_backup>
  <reference>
    <citation>Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. Surv Ophthalmol. 1984 Jan-Feb;28(4):293-322. Review.</citation>
    <PMID>6230745</PMID>
  </reference>
  <reference>
    <citation>Tan DT, Por YM. Current treatment options for corneal ectasia. Curr Opin Ophthalmol. 2007 Jul;18(4):284-9. Review.</citation>
    <PMID>17568202</PMID>
  </reference>
  <reference>
    <citation>Yoshida J, Murata H, Miyai T, Shirakawa R, Toyono T, Yamagami S, Usui T. Characteristics and risk factors of recurrent keratoconus over the long term after penetrating keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2018 Dec;256(12):2377-2383. doi: 10.1007/s00417-018-4131-5. Epub 2018 Sep 8.</citation>
    <PMID>30196480</PMID>
  </reference>
  <reference>
    <citation>Bechrakis N, Blom ML, Stark WJ, Green WR. Recurrent keratoconus. Cornea. 1994 Jan;13(1):73-7.</citation>
    <PMID>8131410</PMID>
  </reference>
  <reference>
    <citation>Abelson MB, Collin HB, Gillette TE, Dohlman CH. Recurrent keratoconus after keratoplasty. Am J Ophthalmol. 1980 Nov;90(5):672-6.</citation>
    <PMID>7004192</PMID>
  </reference>
  <reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.</citation>
    <PMID>18471635</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003 May;135(5):620-7.</citation>
    <PMID>12719068</PMID>
  </reference>
  <reference>
    <citation>Kelly TL, Williams KA, Coster DJ; Australian Corneal Graft Registry. Corneal transplantation for keratoconus: a registry study. Arch Ophthalmol. 2011 Jun;129(6):691-7. doi: 10.1001/archophthalmol.2011.7. Epub 2011 Feb 14.</citation>
    <PMID>21320951</PMID>
  </reference>
  <reference>
    <citation>Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003 Jul;110(7):1396-402.</citation>
    <PMID>12867398</PMID>
  </reference>
  <reference>
    <citation>Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006 Mar 27;81(6):896-901.</citation>
    <PMID>16570014</PMID>
  </reference>
  <reference>
    <citation>Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ; All Contributors. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation. 2008 Dec 27;86(12):1720-4. doi: 10.1097/TP.0b013e3181903b0a.</citation>
    <PMID>19104411</PMID>
  </reference>
  <reference>
    <citation>Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology. 1992 Mar;99(3):403-14.</citation>
    <PMID>1565452</PMID>
  </reference>
  <reference>
    <citation>Binder PS. The effect of suture removal on postkeratoplasty astigmatism. Am J Ophthalmol. 1988 Jun 15;105(6):637-45.</citation>
    <PMID>3287939</PMID>
  </reference>
  <reference>
    <citation>Limberg MB, Dingeldein SA, Green MT, Klyce SD, Insler MS, Kaufman HE. Corneal compression sutures for the reduction of astigmatism after penetrating keratoplasty. Am J Ophthalmol. 1989 Jul 15;108(1):36-42.</citation>
    <PMID>2665502</PMID>
  </reference>
  <reference>
    <citation>Swinger CA. Postoperative astigmatism. Surv Ophthalmol. 1987 Jan-Feb;31(4):219-48. Review.</citation>
    <PMID>3554571</PMID>
  </reference>
  <reference>
    <citation>Troutman RC, Lawless MA. Penetrating keratoplasty for keratoconus. Cornea. 1987;6(4):298-305.</citation>
    <PMID>3319412</PMID>
  </reference>
  <reference>
    <citation>Price FW Jr, Whitson WE, Marks RG. Progression of visual acuity after penetrating keratoplasty. Ophthalmology. 1991 Aug;98(8):1177-85.</citation>
    <PMID>1923353</PMID>
  </reference>
  <reference>
    <citation>Riddle HK Jr, Parker DA, Price FW Jr. Management of postkeratoplasty astigmatism. Curr Opin Ophthalmol. 1998 Aug;9(4):15-28. Review.</citation>
    <PMID>10387463</PMID>
  </reference>
  <reference>
    <citation>Spörl E, Huhle M, Kasper M, Seiler T. [Increased rigidity of the cornea caused by intrastromal cross-linking]. Ophthalmologe. 1997 Dec;94(12):902-6. German.</citation>
    <PMID>9487761</PMID>
  </reference>
  <reference>
    <citation>de Sanctis U, Eandi C, Grignolo F. Phacoemulsification and customized toric intraocular lens implantation in eyes with cataract and high astigmatism after penetrating keratoplasty. J Cataract Refract Surg. 2011 Apr;37(4):781-5. doi: 10.1016/j.jcrs.2011.01.015.</citation>
    <PMID>21420606</PMID>
  </reference>
  <reference>
    <citation>Rajan MS, O'Brart DP, Patel P, Falcon MG, Marshall J. Topography-guided customized laser-assisted subepithelial keratectomy for the treatment of postkeratoplasty astigmatism. J Cataract Refract Surg. 2006 Jun;32(6):949-57.</citation>
    <PMID>16814052</PMID>
  </reference>
  <reference>
    <citation>Arenas E, Maglione A. Laser in situ keratomileusis for astigmatism and myopia after penetrating keratoplasty. J Refract Surg. 1997 Jan-Feb;13(1):27-32.</citation>
    <PMID>9049932</PMID>
  </reference>
  <reference>
    <citation>Belmont SC, Lazzaro DR, Muller JW, Troutman RC. Combined wedge resection and relaxing incisions for astigmatism after penetrating keratoplasty. J Refract Surg. 1995 Nov-Dec;11(6):472-6.</citation>
    <PMID>8624832</PMID>
  </reference>
  <reference>
    <citation>Girard LJ. Corneal compression sutures for the reduction of astigmatism after penetrating keratoplasty. Am J Ophthalmol. 1989 Nov 15;108(5):614.</citation>
    <PMID>2683795</PMID>
  </reference>
  <reference>
    <citation>Fronterrè A, Portesani GP. Relaxing incisions for postkeratoplasty astigmatism. Cornea. 1991 Jul;10(4):305-11.</citation>
    <PMID>1889216</PMID>
  </reference>
  <reference>
    <citation>Bochmann F, Schipper I. Correction of post-keratoplasty astigmatism with keratotomies in the host cornea. J Cataract Refract Surg. 2006 Jun;32(6):923-8.</citation>
    <PMID>16814049</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Joseph B. Ciolino, MD</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Corneal Crosslinking</keyword>
  <keyword>Penetrating Keratoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Flavin Mononucleotide</mesh_term>
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make individual participant data (IPD) available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

